FDA Adds New Data to Gazyva Prescribing Information

Share this content:
The FDA has approved a supplemental license application for Gazyva in combination with chlorambucil chemotherapy.
The FDA has approved a supplemental license application for Gazyva in combination with chlorambucil chemotherapy.

Genentech has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for Gazyva (obinutuzumab) in combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL). 

The sBLA includes new complete response (CR) and minimal residual disease (MRD) data from Stage 2 of the CLL11 study as well as overall survival data from Stage 1 of the study. Stage 1 of the CLL11 trial studied Gazyva plus chlorambucil compared with chlorambucil alone and Stage 2 compared Gazyva plus chlorambucil to rituximab plus chlorambucil.

The sBLA approval adds to the Gazyva prescribing information that Gazyva plus chlorambucil helped patients have a progression-free survival nearly 1 year longer than those who received rituximab plus chlorambucil (26.7 months vs 14.9 months; HR = 0.42; 95% CI: 0.33 - 0.54; P < 0.0001) and that Gazyva plus chlorambucil tripled the number of complete responses compared with rituximab plus chlorambucil (26.1% vs 8.8%).

 In addition, of those who achieved a complete response, more patients who received Gazvya were MRD negative in the bone marrow (19% vs 6%) and the peripheral blood (41% vs 12%) compared with those who received rituximab. Furthermore, 2-year mortality rate was 9% in the Gazyva arm versus 20% in the chlorambucil alone arm (HR = 0.41; 95% CI: 0.23 - 0.74).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs